IMUXHealthcare · BiotechnologyThe 12 Wall Street analysts covering Immunic, Inc. hold a median 12-month price target of $30 — +296.8% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 29 of 100 as at 8 Oct 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.
Consensus tells you what everyone already believes. The model scores Immunic, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (75): Smaller than most of the companies we track.
Value (9): The shares cost a lot relative to the profits and assets behind them.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on IMUX, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +296.8% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 10 Sept 2026 | HC Wainwright & Co. | Reiterates | Buy | $22 |
| 10 Sept 2026 | Wedbush | Reiterates | Outperform | $45 |
| 17 Aug 2026 | Wedbush | Initiates | Outperform | — |
| 17 Aug 2026 | Wedbush | Initiates | Outperform | $45 |
| 22 May 2026 | B. Riley Securities | Maintains | Buy | $40 → $27 |
| 22 May 2026 | B. Riley Securities | Maintains | Buy | — |
| 30 Apr 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 17 Apr 2026 | Stifel | Initiates | Buy | — |
| 15 Apr 2026 | D. Boral Capital | Downgrade | Hold | — |
| 24 Mar 2026 | Guggenheim | Initiates | Buy | — |
| 2 Mar 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 13 Feb 2026 | D. Boral Capital | Maintains | Buy | — |
| 9 Feb 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 7 Jan 2026 | D. Boral Capital | Maintains | Buy | — |
| 14 Nov 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 13 Nov 2025 | D. Boral Capital | Maintains | Buy | — |
| 29 Sept 2025 | Chardan Capital | Initiates | Buy | — |
| 26 Sept 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 25 Sept 2025 | D. Boral Capital | Maintains | Buy | — |
| 8 Aug 2025 | D. Boral Capital | Maintains | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. IMUX appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 8 Oct 2026, Immunic, Inc. returned −15.8% against +16.2% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 83% of US stocks
Cheaper than 77% of US stocks
Cheaper than 59% of US stocks
Higher than 32% of US stocks
Higher than 30% of US stocks
Higher than 10% of US stocks
Higher than 5% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Immunic, Inc. has a market value of $104.1M and an enterprise value of −$47.8M.
Revenue in the twelve months to 30 June 2026: $0.0.
Net income over the same four quarters: −$111.6M.
Free cash flow in the twelve months to 30 June 2026: −$88.0M.
Trailing P/E: −1.2×; forward P/E: −3.1× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Immunic, Inc. employs 100 people.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Immunic, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Immunic said four abstracts on vidofludimus calcium have been accepted for presentation at the 10th Joint ACTRIMS-ECTRIMS Meeting in Toronto, October 21–23. The oral therapy is a Nurr1 activator being developed for neurologic diseases.
Why it matters — The presentations will provide an opportunity for IMUX watchers to learn more about its lead MS drug candidate.
Immunic said four abstracts on vidofludimus calcium were accepted for presentation at MSToronto2026, covering clinical, biomarker and preclinical findings. New Phase 2 CALLIPER open-label extension data showed disability outcomes favoring continuous treatment through extension Week 48, with low treatment discontinuation.
Why it matters — The presentations will provide updates on the investigational therapy’s multiple sclerosis profile, including long-term disability outcomes and other areas of research.
Immunic, Inc. discussed its research and development advances and future directions in relapsing multiple sclerosis during a transcript, as covered by Seeking Alpha. The discussion focuses on the company's ongoing R&D efforts in this indication.
Why it matters — IMUX watchers would want to follow the company's R&D progress in relapsing multiple sclerosis, a key area of its pipeline.
Immunic announced it will host a virtual research and development day focused on relapsing multiple sclerosis on September 9. The event will feature management including the CEO, CMO, CSO, and president/COO, ahead of topline results from its Phase 3 ENSURE trials expected by the end of 2026.
Why it matters — The R&D day gives Immunic watchers an opportunity to hear management discuss its relapsing MS program in detail as the company approaches the anticipated Phase 3 ENSURE topline results.
Immunic, Inc. announced it will host a virtual research and development day focused on relapsing multiple sclerosis on Wednesday, September 9, 2026, at 11:00 am ET. The event is scheduled to be held virtually.
Why it matters — The R&D day will provide IMUX watchers with an opportunity to learn more about the company's pipeline activities related to relapsing multiple sclerosis.
The 12 Wall Street analysts covering Immunic, Inc. have a median 12-month price target of $30, with estimates ranging from $22 to $85. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 12 analysts covering Immunic, Inc., 12 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Immunic, Inc. 29 out of 100 across roughly 4,600 US stocks as at 8 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 8 Oct 2026, Immunic, Inc. ranks 29 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (75 of 100).
No one can know that. What the data says: the median 12-month target from 12 analysts implies +296.8% from the last close, and Ticker Nerd's factor model ranks Immunic, Inc. 29 out of 100 as at 8 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Immunic, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for IMUX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $22 to $85 over the next 12 months.
Immunic, Inc. returned -15.8% over the 12 months to 8 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
Immunic, Inc. is a biotechnology company focused on developing selective oral therapies for chronic inflammatory, autoimmune, and neurologic diseases.
The most recent item we track (Proactive Investors, 7 Oct 2026): "Immunic to present four vidofludimus calcium abstracts at MSToronto2026". Immunic said four abstracts on vidofludimus calcium have been accepted for presentation at the 10th Joint ACTRIMS-ECTRIMS Meeting in Toronto, October 21–23. The oral therapy is a Nurr1 activator being developed for neurologic diseases.
Immunic, Inc. is a biotechnology company focused on developing selective oral therapies for chronic inflammatory, autoimmune, and neurologic diseases. Its current pipeline centers on small-molecule drug candidates designed to modulate immune activity and improve treatment options for conditions such as multiple sclerosis and ulcerative colitis. The company’s lead program, IMU-838, is being studied in late-stage and mid-stage clinical development, while IMU-856 is being advanced for gastrointestinal disorders linked to intestinal barrier dysfunction. Immunic also maintains earlier-stage research programs in immune-mediated diseases. With operations in the United States and Germany, Immunic, Inc. plays a role in the clinical-stage biopharmaceutical market by advancing oral, mechanism-based therapies aimed at complex inflammatory conditions.
CEO Mr. Erik Lundgren · 100 employees · United States · https://imux.com
